516 related articles for article (PubMed ID: 9027612)
1. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
Crawford ED; DeAntoni EP; Ross CA
J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
[TBL] [Abstract][Full Text] [Related]
2. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
5. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy.
Kronz JD; Shaikh AA; Epstein JI
Hum Pathol; 2001 Apr; 32(4):389-95. PubMed ID: 11331955
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer.
Bostwick DG
Am J Clin Pathol; 1994 Oct; 102(4 Suppl 1):S31-7. PubMed ID: 7524305
[TBL] [Abstract][Full Text] [Related]
7. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
Fowler JE; Bigler SA; Miles D; Yalkut DA
J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
9. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
11. The use of PSA as biomarker in nutritional intervention studies of prostate cancer.
van Weerden WM; Schröder FH
Chem Biol Interact; 2008 Jan; 171(2):204-11. PubMed ID: 18177847
[TBL] [Abstract][Full Text] [Related]
12. Influence of patient age on the serum PSA concentration. An important clinical observation.
Oesterling JE; Cooner WH; Jacobsen SJ; Guess HA; Lieber MM
Urol Clin North Am; 1993 Nov; 20(4):671-80. PubMed ID: 7505975
[TBL] [Abstract][Full Text] [Related]
13. Intermediate biomarkers for chemoprevention of prostate cancer.
van der Kwast TH
IARC Sci Publ; 2001; 154():199-205. PubMed ID: 11220659
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
15. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
17. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.
Carter HB; Morrell CH; Pearson JD; Brant LJ; Plato CC; Metter EJ; Chan DW; Fozard JL; Walsh PC
Cancer Res; 1992 Jun; 52(12):3323-8. PubMed ID: 1375867
[TBL] [Abstract][Full Text] [Related]
18. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
19. Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study.
Bosch JL; Tilling K; Bohnen AM; Donovan JL;
Prostate; 2006 Mar; 66(4):335-43. PubMed ID: 16302264
[TBL] [Abstract][Full Text] [Related]
20. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.
Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Tilley WD; Skinner JM; Horsfall DJ
Clin Cancer Res; 1997 Jun; 3(6):983-92. PubMed ID: 9815775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]